Search Results - "SATOUCHI, Miyako"

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration by Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.

“…MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs) 1 . These alterations are associated with increased MET activity and…”
Get full text

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study by Goss, Glenwood, Dr Prof, Tsai, Chun-Ming, Prof, Shepherd, Frances A, Prof, Bazhenova, Lyudmila, Prof, Lee, Jong Seok, MD, Chang, Gee-Chen, MD, Crino, Lucio, MD, Satouchi, Miyako, MD, Chu, Quincy, MD, Hida, Toyoaki, MD, Han, Ji-Youn, Prof, Juan, Oscar, MD, Dunphy, Frank, Prof, Nishio, Makoto, MD, Kang, Jin-Hyoung, MD, Majem, Margarita, MD, Mann, Helen, MSc, Cantarini, Mireille, MD, Ghiorghiu, Serban, MD, Mitsudomi, Tetsuya, Prof

“…Summary Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor…”
Get full text

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial by Hida, Toyoaki, MD, Nokihara, Hiroshi, MD, Kondo, Masashi, MD, Kim, Young Hak, MD, Azuma, Koichi, MD, Seto, Takashi, MD, Takiguchi, Yuichi, Prof, Nishio, Makoto, MD, Yoshioka, Hiroshige, MD, Imamura, Fumio, MD, Hotta, Katsuyuki, Prof, Watanabe, Satoshi, MD, Goto, Koichi, MD, Satouchi, Miyako, MD, Kozuki, Toshiyuki, MD, Shukuya, Takehito, MD, Nakagawa, Kazuhiko, Prof, Mitsudomi, Tetsuya, Prof, Yamamoto, Nobuyuki, Prof, Asakawa, Takashi, PhD, Asabe, Ryoichi, MS, Tanaka, Tomohiro, MS, Tamura, Tomohide, Dr

“…Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability…”
Get full text

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer by Shaw, Alice T, Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Lin, Chia-Chi, Soo, Ross A, Riely, Gregory J, Ou, Sai-Hong Ignatius, Clancy, Jill S, Li, Sherry, Abbattista, Antonello, Thurm, Holger, Satouchi, Miyako, Camidge, D Ross, Kao, Steven, Chiari, Rita, Gadgeel, Shirish M, Felip, Enriqueta, Martini, Jean-François

“…Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity…”
Get full text

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study by Katsuya, Yuki, Horinouchi, Hidehito, Seto, Takashi, Umemura, Shigeki, Hosomi, Yukio, Satouchi, Miyako, Nishio, Makoto, Kozuki, Toshiyuki, Hida, Toyoaki, Sukigara, Tamie, Nakamura, Kenichi, Kuchiba, Aya, Ohe, Yuichiro

“…Thymic carcinoma (TC) is a rare cancer with a poor prognosis and limited treatment options, especially after relapse. In this open-label, two-stage,…”
Get full text

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer by Nakagawa, Kazuhiko, Hida, Toyoaki, Nokihara, Hiroshi, Morise, Masahiro, Azuma, Koichi, Kim, Young Hak, Seto, Takashi, Takiguchi, Yuichi, Nishio, Makoto, Yoshioka, Hiroshige, Kumagai, Toru, Hotta, Katsuyuki, Watanabe, Satoshi, Goto, Koichi, Satouchi, Miyako, Kozuki, Toshiyuki, Koyama, Ryo, Mitsudomi, Tetsuya, Yamamoto, Nobuyuki, Asakawa, Takashi, Hayashi, Morihiko, Hasegawa, Wakako, Tamura, Tomohide

“…•Final PFS data and second pre-planned interim analysis of OS and safety from J-ALEX.•Sustained improvement in IRF-assessed PFS demonstrated with…”
Get full text

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial by Yoh, Kiyotaka, Dr, Seto, Takashi, MD, Satouchi, Miyako, MD, Nishio, Makoto, MD, Yamamoto, Noboru, MD, Murakami, Haruyasu, MD, Nogami, Naoyuki, MD, Matsumoto, Shingo, MD, Kohno, Takashi, PhD, Tsuta, Koji, Prof, Tsuchihara, Katsuya, MD, Ishii, Genichiro, MD, Nomura, Shogo, MSc, Sato, Akihiro, MD, Ohtsu, Atsushi, MD, Ohe, Yuichiro, MD, Goto, Koichi, MD

“…Summary Background RET rearrangements are rare oncogenic alterations in non-small-cell lung cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase…”
Get full text

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial by Mitsudomi, Tetsuya, Dr, Morita, Satoshi, Prof, Yatabe, Yasushi, MD, Negoro, Shunichi, MD, Okamoto, Isamu, MD, Tsurutani, Junji, MD, Seto, Takashi, MD, Satouchi, Miyako, MD, Tada, Hirohito, MD, Hirashima, Tomonori, MD, Asami, Kazuhiro, MD, Katakami, Nobuyuki, MD, Takada, Minoru, Prof, Yoshioka, Hiroshige, MD, Shibata, Kazuhiko, MD, Kudoh, Shinzoh, MD, Shimizu, Eiji, Prof, Saito, Hiroshi, MD, Toyooka, Shinichi, MD, Nakagawa, Kazuhiko, Prof, Fukuoka, Masahiro, Prof

“…Summary Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor ( EGFR ) gene respond well to the…”
Get full text

Multiplex gene‐panel testing for lung cancer patients by Yatabe, Yasushi, Sunami, Kuniko, Goto, Koichi, Nishio, Kazuto, Aragane, Naoko, Ikeda, Sadakatsu, Inoue, Akira, Kinoshita, Ichiro, Kimura, Hideharu, Sakamoto, Tomohiro, Satouchi, Miyako, Shimizu, Junichi, Tsuta, Koji, Toyooka, Shinichi, Nishino, Kazumi, Hatanaka, Yutaka, Matsumoto, Shingo, Mikubo, Masashi, Yokose, Tomoyuki, Dosaka‐Akita, Hirotoshi

“…The year 2019 was considered to be the first year of cancer genome medicine in Japan, with three gene‐panel tests using next‐generation sequencing (NGS)…”
Get full text

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial by Goto, Koichi, Dr, Ohe, Yuichiro, MD, Shibata, Taro, MSc, Seto, Takashi, MD, Takahashi, Toshiaki, MD, Nakagawa, Kazuhiko, Prof, Tanaka, Hiroshi, MD, Takeda, Koji, MD, Nishio, Makoto, MD, Mori, Kiyoshi, MD, Satouchi, Miyako, MD, Hida, Toyoaki, MD, Yoshimura, Naruo, MD, Kozuki, Toshiyuki, MD, Imamura, Fumio, MD, Kiura, Katsuyuki, Prof, Okamoto, Hiroaki, MD, Sawa, Toshiyuki, MD, Tamura, Tomohide, MD

“…Summary Background Etoposide and irinotecan are key drugs in the treatment of small-cell lung cancer. We did this study to investigate whether combined…”
Get full text

Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer by Tsujino, Kayoko, Hashimoto, Tomohisa, Shimada, Temiko, Yoden, Eisaku, Fujii, Osamu, Ota, Yosuke, Satouchi, Miyako, Negoro, Shunichi, Adachi, Shuji, Soejima, Toshinori

“…We aimed to develop a more accurate model for predicting severe radiation pneumonitis (RP) after concurrent chemoradiotherapy for non-small-cell lung cancer…”
Get more information

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105 by YAMAMOTO, Nobuyuki, NAKAGAWA, Kazuhiko, SAWA, Toshiyuki, YOKOTA, Soichiro, SETO, Takashi, IMAMURA, Fumio, SAKA, Hideo, IWAMOTO, Yasuo, SEMBA, Hiroshi, CHIBA, Yasutaka, UEJIMA, Hisao, FUKUOKA, Masahiro, NISHIMURA, Yasumasa, TSUJINO, Kayoko, SATOUCHI, Miyako, KUDO, Shinzoh, HIDA, Toyoaki, KAWAHARA, Masaaki, TAKEDA, Koji, KATAKAMI, Nobuyuki

“…This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-generation chemotherapy with second-generation chemotherapy in…”
Get full text

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review by Nishiyama, Akihiro, Hattori, Yoshihiro, Takeuchi, Shinji, Tanimoto, Azusa, Satouchi, Miyako, Murayama, Toshinori, Yano, Seiji

“…Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events…”
Get full text

Clinical results of carbon ion radiotherapy for inoperable stage I non-small cell lung cancer: A Japanese national registry study (J-CROS-LUNG) by Kubo, Nobuteru, Suefuji, Hiroaki, Nakajima, Mio, Tokumaru, Sunao, Okano, Naoko, Yoshida, Daisaku, Suzuki, Osamu, Ishikawa, Hitoshi, Satouchi, Miyako, Nakayama, Haruhiko, Shioyama, Yoshiyuki

“…•This prospective nationwide registry study included all CIRT institutions in Japan.•The 3 year overall survival and cause-specific survival rates were 59.3%…”
Get full text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA by John, Thomas, Sakai, Hiroshi, Ikeda, Satoshi, Cheng, Ying, Kasahara, Kazuo, Sato, Yuki, Nakahara, Yoshiro, Takeda, Masayuki, Kaneda, Hiroyasu, Zhang, Helong, Maemondo, Makoto, Minato, Koichi, Hisada, Takeshi, Misumi, Yuki, Satouchi, Miyako, Hotta, Katsuyuki, Li, Ang, Oukessou, Abderrahim, Lu, Shun

“…Background CheckMate 9LA, a phase 3, randomized, open-label study in first-line advanced non-small cell lung cancer (NSCLC), showed significantly improved…”
Get full text

KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer by Nishio, Makoto, Takahashi, Toshiaki, Yoshioka, Hiroshige, Nakagawa, Kazuhiko, Fukuhara, Tatsuro, Yamada, Kazuhiko, Ichiki, Masao, Tanaka, Hiroshi, Seto, Takashi, Sakai, Hiroshi, Kasahara, Kazuo, Satouchi, Miyako, Han, Shi Rong, Noguchi, Kazuo, Shimamoto, Takashi, Kato, Terufumi

“…Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has been shown to improve overall survival (OS) in patients with previously…”
Get full text

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study by Sueoka‐Aragane, Naoko, Katakami, Nobuyuki, Satouchi, Miyako, Yokota, Soichiro, Aoe, Keisuke, Iwanaga, Kentaro, Otsuka, Kojiro, Morita, Satoshi, Kimura, Shinya, Negoro, Shunichi

“…Use of plasma DNA to detect mutations has spread widely as a form of liquid biopsy. EGFR T790M has been observed in half of lung cancer patients who have…”
Get full text

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer by Yasuda, Yuichiro, Urata, Yoshiko, Tohnai, Rie, Ito, Shoichi, Kawa, Yoshitaka, Kono, Yuko, Hattori, Yoshihiro, Tsuda, Masahiro, Sakuma, Toshiko, Negoro, Shunichi, Satouchi, Miyako

“…We herein report a case of immune-related colitis induced by the long-term use of nivolumab. A 62-year-old Japanese man was treated with nivolumab at 3 mg/kg…”
Get full text

Glucose metabolism‐targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor‐induced drug‐tolerant persisters by Kunimasa, Kei, Nagano, Tatsuya, Shimono, Yohei, Dokuni, Ryota, Kiriu, Tatsunori, Tokunaga, Shuntaro, Tamura, Daisuke, Yamamoto, Masatsugu, Tachihara, Motoko, Kobayashi, Kazuyuki, Satouchi, Miyako, Nishimura, Yoshihiro

“…In pathway‐targeted cancer drug therapies, the relatively rapid emergence of drug‐tolerant persisters (DTPs) substantially limits the overall therapeutic…”
Get full text

Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study by OKAMOTO, Isamu, YOSHIOKA, Hiroshige, KUDOH, Shinzoh, SATOUCHI, Miyako, IKEDA, Norihiko, IWAMOTO, Yasuo, SAWA, Toshiyuki, MIYAZAKI, Masaki, TAMURA, Kenji, KURATA, Takayasu, FUKUOKA, Masahiro, NAKAGAWA, Kazuhiko, MORITA, Satoshi, ANDO, Masahiko, TAKEDA, Koji, SETO, Takashi, YAMAMOTO, Nobuyuki, SAKA, Hideo, ASAMI, Kazuhiro, HIRASHIMA, Tomonori

“…The primary goal of this open-label, multicenter, randomized phase III trial was to determine whether treatment with carboplatin plus the oral fluoropyrimidine…”
Get full text